Business Context and Reporting Period
Company: Arvinas, Inc. (ARVN)
Filing Type: Form 8-K (Current Report)
Date of Report: October 20, 2025
Reporting Period: Event-based report regarding clinical trial data presented at the 2025 European Society for Medical Oncology Congress (ESMO 2025).
Key Financial Metrics
This filing is a regulatory disclosure of clinical trial results and does not contain financial statements. The filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes and Clinical Updates
- Phase 3 VERITAC-2 Trial (Vepdegestrant): New patient-reported outcomes (PRO) data were announced for vepdegestrant, a PROTAC estrogen receptor degrader developed with Pfizer Inc. for ER+/HER2- advanced or metastatic breast cancer with ESR1 mutations.
- PRO Results: In patients with ESR1-mutated disease, vepdegestrant demonstrated a statistically significant reduced risk of deterioration compared to fulvestrant in several domains, including overall health status, pain severity, and functioning (role, cognitive, emotional, and social).
- Consistency: Vepdegestrant showed a reduced risk of deterioration versus fulvestrant across all PRO domains.
- Phase 2 TACTIVE-N Trial: Results presented for neoadjuvant vepdegestrant in postmenopausal women with ER+/HER2- localized breast cancer. The drug demonstrated biological and clinical activity in a treatment-naïve, predominantly ESR1 wild-type population.
Guidance, Outlook, and Risks
Management Commentary: The PRO data from the VERITAC-2 trial support the clinical benefit of vepdegestrant in the specified patient population. The TACTIVE-N results indicate activity in a different patient demographic (localized, treatment-naïve).
Risks and Contingencies: The filing notes that the information in Item 7.01 and Exhibit 99.1 is not deemed "filed" for purposes of Section 18 of the Exchange Act and is not subject to the liabilities of that section, nor is it incorporated by reference into other filings except as expressly set forth.
Investor Verification Checklist
- Verify the full text of the press release (Exhibit 99.1) for detailed statistical data on the PRO domains.
- Confirm the specific statistical significance levels and hazard ratios for the VERITAC-2 trial results.
- Review the patient population details for the TACTIVE-N trial to understand the scope of the "predominantly ESR1 wild-type" claim.
- Monitor subsequent regulatory filings for any updates on the development timeline or partnership status with Pfizer Inc.